866-997-4948(US-Canada Toll Free)

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

Published By :

GlobalData

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 182 Pages

PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

Summary

Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. In order to assist our clients with navigating the burgeoning amount information arising as a result of the rapidly growing field of IO clinical research, GlobalData is offering a comprehensive analysis of both pipeline and marketed active immunity IO therapies.

Scope

Key Topics Covered -
- Immune Checkpoint Modulators - Trends in Clinical Trial Development
- Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators
- Emergence of New Immune Checkpoint Targets
- Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies
- Cell Vaccines: Steady Development Stimulated by Prior IO Success
- Promising IO-IO Combinations Utilizing Oncolytic Viruses

Reasons to buy

- The PharmaFocus consists of a highly-visual slide deck that is intended to facilitate the dissemination of aggregated data and insights from analyses of over 800 IO products that are either marketed or in Phase I-III of clinical development.
- Types of graphical analyses include - Cumulative Plots, Aggregated Bubble Plots, Pie Charts, Matrix Analyses
- Unique, actionable insights applicable to IO drugs in five major categories: Immune Checkpoint Modulators, Cellular Immunotherapies, Oncolytic Viruses, Peptide Vaccines, and Bispecific T-Cell Engagers are provided in this report.
- Analysis of over 4000 clinical trials enrolling patients with 18 solid tumors and eight hematological cancers are included.
Table of Contents
1. Preface
1.1 Related Reports 4
1.2 Upcoming Reports 5
1.3 Abbreviations 6
2. Immuno-Oncology Product Definition and Classification 7
3. Recent Timeline of Immuno-Oncology Approvals 11
4. Immune Checkpoint Modulators - Trends in Clinical Trial Development 19
4.1 Clinical Trial Activity for Checkpoint Modulators Remains Essentially Driven by PD-(L)1 and CTLA-4 Targeting Agents 20-25
4.2 Academic Institutions Are Key Drivers for Early Stage Clinical Research, but Patient Recruitment is Highly Dependent on Companies 26-32
4.3 Geographic Locations of Trials Assessing Immune Checkpoint Modulators 33-37
5. Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators 38
5.1 Clinical Positioning of Marketed PD-(L)1 Inhibitors 39-45
5.2 Commercial Attributes of Marketed PD-(L)1 Checkpoint Modulators 46-56
5.3 Dynamic of Clinical Development for Marketed PD-(L)1 Checkpoint Modulators 57-61
5.4 Clinical Development Coverage of Marketed PD-(L)1 Checkpoint Modulators in Solid Tumors and Blood Cancers 62-71
6. Emergence of New Immune Checkpoint Targets 72
6.1 Emergence of New Checkpoint Targets in Clinical Development 73-79
6.2 Clinical Development Coverage of Emerging Targets in Solid Tumors and Blood Cancers - Matrix Analysis 80-89
7. Cellular Immunotherapies in Clinical Development 90
7.1 Clinical Development of Cellular Immunotherapies 91-98
7.2 Clinical Development of Cytotoxic Cellular Immunotherapies 99-110
8. Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies 111
8.1 Development of and Opportunities for CAR Cell Therapies 112-123
8.2 Development of CAR Cell Therapies in Blood Cancers 124-130
8.3 Development of CAR Cell Therapies in Solid Tumors 131-137
9. Cell Vaccines: Steady Development Stimulated by Prior IO Success 138
9.1 Trends in Clinical Development of Cancer Vaccines 139-152
10. T-cell Redirecting Therapies: Comparison Between CAR Cell Therapies and Bispecific T-Cell Engager Antibodies 153
10.1 Development of CAR Cell Therapies and Bispecific T-Cell Engagers 154-161
11. Promising IO-IO Combinations Utilizing Oncolytic Viruses 162
11.1 Combination Strategies of Oncolytic Viruses with Other IO Agents Create New Clinical Opportunities 163-169
12. Appendix 170
12.1 Inclusion Criteria for IO Products 171
12.2 Exclusion Criteria for IO Products 172
12.3 Identification of Immuno-Oncology Products Based on Targets and Molecule Types 173
12.4 Data Export from the Pharma Intelligence Center 174
12.5 Primary Research 175-176
12.6 Bibliography 177
12.7 About the Authors 178-179
12.8 About GlobalData 180
12.9 Contact Us 181
12.10 Disclaimer 182



Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *